Why Is DAVITA INC (DVA) Stock Down Today?

Why DVA stock is down today

DaVita Inc. shares fell 17.24% to $188.67 in Monday trading, marking a sharp decline despite the company reporting strong second-quarter 2026 results. The stock opened with a -6.1% gap down and continued to fall throughout the session, hitting a low of $187.00 before closing near that level. The move reflects investor reaction to mixed signals from the company and broader market dynamics.

What Happened

DaVita reported improved operating margins, increased patient treatment volumes, and reaffirmed its annual guidance for adjusted earnings per share. The company highlighted a 16.3% operating margin for the quarter and plans to expand hemodialysis services. However, the stock declined after hours following the earnings report, with shares falling 7% despite beating revenue and earnings estimates. The SEC 8-K filing on August 4 disclosed the results and reaffirmed the company’s annual forecast. Meanwhile, a Form 4 filing revealed that Berkshire Hathaway sold 182,980 DaVita shares at an average price of $199.55 per share. This followed recent insider sales by DaVita’s CEO and other executives.

What The Data Shows

The stock opened at $214.00 and traded as high as $216.97 before declining sharply. Volume reached 0.5 million shares, or 0.7 times the 3-month daily average. The stock is currently trading near its 52-week low of $101.00, down from a 52-week high of $247.49. DaVita has a market cap of $15.0B, a P/E ratio of 21.9, and trailing 12-month revenue growth of 6.7%. Recent insider transactions show 6 sells totaling $71.1M in the last 90 days, with no buys reported.

What To Watch

DaVita has not scheduled earnings for the near term, but investors will monitor coverage breadth and market sentiment for further direction. The company’s ability to maintain its guidance and manage ESRD reimbursement risks will remain key focal points.